Free Trial
NASDAQ:IMNM

Immunome Q1 2025 Earnings Report

Immunome logo
$9.13 +0.01 (+0.11%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$9.38 +0.25 (+2.73%)
As of 06/6/2025 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.66
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$2.93 million
Expected Revenue
$0.46 million
Beat/Miss
Beat by +$2.47 million
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Immunome's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Immunome Earnings Headlines

Lifesci Capital Has Bullish Outlook for Immunome Q2 Earnings
The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat